Eliana Merle Analyst Performance

Eliana Merle is a stock analyst at UBS Group in the medical sector, covering 25 publicly traded companies. Over the past year, Eliana Merle has issued 24 stock ratings, including buy and hold recommendations. While full access to Eliana Merle's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eliana Merle's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

70 Last 7 Years

Buy Recommendations

86.57% 58 Buy Ratings

Companies Covered

25 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	86.6%	57 ratings
Hold	13.4%	9 ratings
Sell	0.0%	0 ratings

Out of 67 total stock ratings issued by Eliana Merle at UBS Group, the majority (86.6%) have been Buy recommendations, followed by 13.4% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  ARVN

  May 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  CBAY

  Apr 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	25 companies

Eliana Merle, an analyst at UBS Group, currently covers 25 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 25 companies	100.0%

Eliana Merle of UBS Group specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 17 companies	68.0%
MED - DRUGS 5 companies	20.0%
PHARMACEUTICAL PREPARATIONS 2 companies	8.0%
MED - GENERIC DRG 1 company	4.0%

Eliana Merle's Ratings History at UBS Group

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
BBIO BridgeBio Pharma	9/12/2025	Boost Price Target	$52.77	$82.00	Buy	$0.00 00.00% ROI
ALT Altimmune	8/13/2025	Lower Price Target	$3.85	$24.00	Buy	$0.00 00.00% ROI
RAPT Rapt Therapeutics	8/12/2025	Set Price Target	$9.52	$9.00	Neutral	$0.00 00.00% ROI
MDGL Madrigal Pharmaceuticals	8/12/2025	Reiterated Rating	$350.83	$523.00	Buy	$0.00 00.00% ROI
ANAB AnaptysBio	8/12/2025	Reiterated Rating	$20.10	$20.00	Neutral	$0.00 00.00% ROI
ASND Ascendis Pharma A/S	8/8/2025	Reiterated Rating	$183.33	$307.00	Buy	$0.00 00.00% ROI
BMRN BioMarin Pharmaceutical	8/5/2025	Boost Price Target	$60.31	$114.00	Buy	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$398.49	$550.00	Buy	$0.00 00.00% ROI
SRPT Sarepta Therapeutics	7/21/2025	Reiterated Rating	$13.56		Neutral	$0.00 00.00% ROI
PROK ProKidney	7/15/2025	Boost Price Target	$3.84	$8.00	Buy	$0.00 00.00% ROI
CVAC CureVac	6/26/2025	Downgrade	$5.42	$5.50	Neutral	$0.00 00.00% ROI
RAPT Rapt Therapeutics	5/22/2025	Lower Price Target	$7.10	$8.00	Neutral	$0.00 00.00% ROI
ARVN Arvinas	5/15/2025	Lower Price Target	$5.93	$21.00	Buy	$0.00 00.00% ROI
KYMR Kymera Therapeutics	5/13/2025	Lower Price Target	$31.02	$70.00	Buy	$0.00 00.00% ROI
MRNA Moderna	5/2/2025	Lower Price Target	$27.61	$70.00	Buy	$0.00 00.00% ROI
MDGL Madrigal Pharmaceuticals	5/2/2025	Boost Price Target	$315.48	$458.00	Buy	$0.00 00.00% ROI
BBIO BridgeBio Pharma	4/30/2025	Boost Price Target	$38.57	$72.00	Buy	$0.00 00.00% ROI
CVAC CureVac	4/30/2025	Lower Price Target	$3.65	$12.00	Buy	$0.00 00.00% ROI
APLS Apellis Pharmaceuticals	4/29/2025	Initiated Coverage	$17.96	$44.00	Overweight	$0.00 00.00% ROI
BMRN BioMarin Pharmaceutical	2/20/2025	Boost Price Target	$67.92	$113.00	Buy	$0.00 00.00% ROI
MRNA Moderna	2/19/2025	Lower Price Target	$36.15	$78.00	Buy	$0.00 00.00% ROI
ETNB 89BIO	1/31/2025	Boost Price Target	$9.44	$38.00	Buy	$0.00 00.00% ROI
AKRO Akero Therapeutics	1/31/2025	Boost Price Target	$53.43	$109.00	Buy	$0.00 00.00% ROI
ZNTL Zentalis Pharmaceuticals	1/28/2025	Lower Price Target	$2.38	$2.20	Neutral	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.